Pricing Log in Create free account

Kairos Pharma, Ltd. (KAPA) vs Valion Bio, Inc. (VBIO)

Kairos Pharma, Ltd. and Valion Bio, Inc. are both Biotechnology companies. Kairos Pharma, Ltd. and Valion Bio, Inc. are of similar size ($2.4M and $2.3M). Across the 10 metrics below, Kairos Pharma, Ltd. leads on 6 and Valion Bio, Inc. on 4.

Valuation

Metric KAPA VBIO Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.33 9.71
P/B 0.44 0.04 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.14 n/m 0.64
EV/Sales n/m 11.28 9.21
Earnings yield (326.58%) (15,509.47%) (33.15%)
Free cash flow yield (216.16%) (9,619.81%) (25.50%)

Profitability

Metric KAPA VBIO Biotechnology median
Gross margin — (58.09%) 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (113.96%) (489.30%) (56.36%)
Return on assets (104.32%) (104.96%) (48.04%)
Return on invested capital (322.91%) (61.01%) 0.00%

Growth

Metric KAPA VBIO Biotechnology median
Revenue growth (TTM) — (49.63%) 6.02%
EPS growth (last fiscal year) (30.44%) 60.16% 30.26%
Revenue growth, 5-year CAGR — 13.18% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA VBIO Biotechnology median
Debt to equity 0.00 0.62 0.00
Current ratio 11.98 1.11 4.72
Net debt to EBITDA 1.65 0.79 0.96

Dividend

Metric KAPA VBIO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KAPA VBIO Biotechnology median
Market cap 2.27m 2.39m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack